TOP

CEFOXITIN(cefoxitin sodium)powder, for solution

2014-06-12 14:38:55 来源: 作者: 【大中小】浏览:347次评论:0条

Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefoxitin for Injection and other antibacterial drugs, Cefoxitin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Cefoxitin for Injection, USP contains cefoxitin sodium a semi-synthetic, broad-spectrum cephalosporin antibiotic for parenteral administration. It is derived from cephalosporin C, which is produced by Cephalosporium Acremonium. It is the sodium salt of 3-(hydroxymethyl)-7-methoxy-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate carbamate (ester). The molecular formula is C16H16N3NaO7S2, and the structural formula is:

Image of Chemical Structure

Cefoxitin for Injection, USP contains approximately 53.8 mg (2.3 milliequivalents) of sodium per gram of cefoxitin activity. Solutions of Cefoxitin for Injection, USP range from colorless to light amber in color. The pH of freshly constituted solutions usually ranges from 4.2 to 7.0.

Each conventional vial contains sterile cefoxitin sodium, USP equivalent to 1 or 2 g cefoxitin.

CLINICAL PHARMACOLOGY

Clinical Pharmacology

Following an intravenous dose of 1 gram, serum concentrations were 110 mcg/mL at 5 minutes, declining to less than 1 mcg/mL at 4 hours. The half-life after an intravenous dose is 41 to 59 minutes. Approximately 85% of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Probenecid slows tubular excretion and produces higher serum levels and increases the duration of measurable serum concentrations.

Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.

In a published study of geriatric patients ranging in age from 64 to 88 years with normal renal function for their age (creatinine clearance ranging from 31.5 to 174.0 mL/min), the half-life for cefoxitin ranged from 51 to 90 minutes, resulting in higher plasma concentrations than in younger adults. These changes were attributed to decreased renal function associated with the aging process.

Microbiology

The bactericidal action of cefoxitin results from inhibition of cell wall synthesis. Cefoxitin has in vitro activity against a wide range of gram-positive and gram-negative organisms. The methoxy group in the 7α position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.

Cefoxitin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Aerobic gram-positive microorganisms

: Staphylococcus aureusa (including penicillinase-producing strains)
: Staphylococcus epidermidisa
: Streptococcus agalactiae
: Streptococcus pneumoniae
: Streptococcus pyogenes
: a Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin.
: Most strains of enterococci, e.g. Enterococcus faecalis, are resistant.

Aerobic gram-negative microorganisms

: Escherichia coli
: Haemophilus influenzae
: Klebsiella spp. (including K. pneumoniae)
: Morganella morganii
: Neisseria gonorrhoeae (including penicillinase-producing strains)
: Proteus mirabilis
: Proteus vulgaris
: Providencia spp. (including Providencia rettgeri)

Anaerobic gram-positive microorganisms

: Clostridium spp.
: Peptococcus niger
: Peptostreptococcus spp.

Anaerobic gram-negative microorganisms

: Bacteroides distasonis
: Bacteroides fragilis
: Bacteroides ovatus
: Bacteroides thetaiotaomicron
: Bacteroides spp.

The following in vitro data are available, but their clinical significance is unknown.

Cefoxitin exhibits in vitro minimum inhibitory concentrations (MIC’s) of 8 mcg/mL or less for aerobic microorganisms and 16 mcg/mL or less for anaerobic microorganisms against most (≥90%) strains of the following microorganisms; however, the safety and effectiveness of cefoxitin in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.